Roche Says Still Discussing Actemra with FDA

October 21, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

ZURICH, Oct 21 (Reuters) - Roche Holding AG is still discussing what additional information is required for approval of its Actemra rheumatoid arthritis drug with U.S. regulators, the Swiss company said on Tuesday.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory Europe

Food and Drug Administration (FDA) Roche